8:37 AM
 | 
Jul 27, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

resTORbio forging ahead with anti-infective after Phase IIb readout

Data from Part 2 of a Phase IIb trial evaluating RTB101 from resTORbio Inc. (NASDAQ:TORC) to prevent respiratory tract infections showed that all three dose regimens of the candidate missed the study's primary endpoint vs. placebo. However, based on a prespecified pooled analysis of the trial's Parts 1 and 2 in which one dose did significantly improve the primary endpoint, resTORbio plans to start Phase III trials next year of that dose.

The two-part Phase IIb trial enrolled a total of 652 elderly patients at increased risk of morbidity and mortality associated with respiratory tract infections. Part 1 evaluated once-daily 5 and 10 mg doses of RTB101 vs. placebo; patients...

Read the full 526 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >